AIRLINK 167.80 Decreased By ▼ -10.36 (-5.81%)
BOP 9.78 Decreased By ▼ -0.26 (-2.59%)
CNERGY 7.99 Decreased By ▼ -0.23 (-2.8%)
CPHL 88.00 Decreased By ▼ -4.50 (-4.86%)
FCCL 44.00 Decreased By ▼ -1.77 (-3.87%)
FFL 15.56 Decreased By ▼ -0.34 (-2.14%)
FLYNG 28.05 Decreased By ▼ -0.45 (-1.58%)
HUBC 138.25 Decreased By ▼ -3.86 (-2.72%)
HUMNL 12.46 Decreased By ▼ -0.35 (-2.73%)
KEL 4.27 Decreased By ▼ -0.09 (-2.06%)
KOSM 5.59 Decreased By ▼ -0.33 (-5.57%)
MLCF 64.80 Decreased By ▼ -1.49 (-2.25%)
OGDC 212.03 Decreased By ▼ -2.33 (-1.09%)
PACE 5.74 Decreased By ▼ -0.28 (-4.65%)
PAEL 45.00 Decreased By ▼ -0.90 (-1.96%)
PIAHCLA 17.20 Decreased By ▼ -0.32 (-1.83%)
PIBTL 9.27 Decreased By ▼ -0.50 (-5.12%)
POWER 14.50 Increased By ▲ 0.30 (2.11%)
PPL 167.00 Decreased By ▼ -2.82 (-1.66%)
PRL 30.63 Decreased By ▼ -2.55 (-7.69%)
PTC 21.24 Decreased By ▼ -0.31 (-1.44%)
SEARL 90.21 Decreased By ▼ -3.19 (-3.42%)
SSGC 41.10 Decreased By ▼ -0.01 (-0.02%)
SYM 14.53 Decreased By ▼ -0.93 (-6.02%)
TELE 7.43 Decreased By ▼ -0.25 (-3.26%)
TPLP 9.48 Decreased By ▼ -0.37 (-3.76%)
TRG 65.28 Decreased By ▼ -1.70 (-2.54%)
WAVESAPP 9.59 Decreased By ▼ -0.23 (-2.34%)
WTL 1.32 Decreased By ▼ -0.01 (-0.75%)
YOUW 3.72 Decreased By ▼ -0.10 (-2.62%)
AIRLINK 167.80 Decreased By ▼ -10.36 (-5.81%)
BOP 9.78 Decreased By ▼ -0.26 (-2.59%)
CNERGY 7.99 Decreased By ▼ -0.23 (-2.8%)
CPHL 88.00 Decreased By ▼ -4.50 (-4.86%)
FCCL 44.00 Decreased By ▼ -1.77 (-3.87%)
FFL 15.56 Decreased By ▼ -0.34 (-2.14%)
FLYNG 28.05 Decreased By ▼ -0.45 (-1.58%)
HUBC 138.25 Decreased By ▼ -3.86 (-2.72%)
HUMNL 12.46 Decreased By ▼ -0.35 (-2.73%)
KEL 4.27 Decreased By ▼ -0.09 (-2.06%)
KOSM 5.59 Decreased By ▼ -0.33 (-5.57%)
MLCF 64.80 Decreased By ▼ -1.49 (-2.25%)
OGDC 212.03 Decreased By ▼ -2.33 (-1.09%)
PACE 5.74 Decreased By ▼ -0.28 (-4.65%)
PAEL 45.00 Decreased By ▼ -0.90 (-1.96%)
PIAHCLA 17.20 Decreased By ▼ -0.32 (-1.83%)
PIBTL 9.27 Decreased By ▼ -0.50 (-5.12%)
POWER 14.50 Increased By ▲ 0.30 (2.11%)
PPL 167.00 Decreased By ▼ -2.82 (-1.66%)
PRL 30.63 Decreased By ▼ -2.55 (-7.69%)
PTC 21.24 Decreased By ▼ -0.31 (-1.44%)
SEARL 90.21 Decreased By ▼ -3.19 (-3.42%)
SSGC 41.10 Decreased By ▼ -0.01 (-0.02%)
SYM 14.53 Decreased By ▼ -0.93 (-6.02%)
TELE 7.43 Decreased By ▼ -0.25 (-3.26%)
TPLP 9.48 Decreased By ▼ -0.37 (-3.76%)
TRG 65.28 Decreased By ▼ -1.70 (-2.54%)
WAVESAPP 9.59 Decreased By ▼ -0.23 (-2.34%)
WTL 1.32 Decreased By ▼ -0.01 (-0.75%)
YOUW 3.72 Decreased By ▼ -0.10 (-2.62%)
BR100 12,255 Decreased By -261.8 (-2.09%)
BR30 36,723 Decreased By -919.8 (-2.44%)
KSE100 115,020 Decreased By -2206.3 (-1.88%)
KSE30 35,328 Decreased By -691.3 (-1.92%)

BEIJING: China has approved its first locally developed messenger RNA (mRNA) vaccine against Covid-19, its manufacturer said Wednesday, months after the relaxation of strict Covid-zero regulations sparked a surge in cases.

The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for “emergency use” by Beijing’s health regulator, the company said in a statement.

It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details.

China to reopen borders to foreign tourists for first time since 2020

mRNA vaccines are considered among the most effective in reducing severe infections and deaths.

While traditional vaccines use a weakened or inactivated germ to prepare the body for a future attack from the real virus, mRNA deploys snippets of genetic material that carry instructions showing the body’s cells how to produce a protein – in this case, the spike protein on the coronavirus that causes Covid.

The body’s immune system then triggers antibodies to fight off that spike protein, making it ready for when the real coronavirus comes knocking.

Beijing has refused to greenlight mRNA-based vaccines from foreign firms Pfizer-BioNTech and Moderna for public use.

Its vaccination shortfall was widely believed to have led to more severe infections and deaths after lockdowns and mandatory quarantine rules were suddenly dropped in December.

Other Chinese drugmakers including CanSino have previously said they were developing mRNA-based shots to help the country bridge its immunisation gap.

Comments

Comments are closed.